ARTICLE SUMMARY:
At the recent EuroPCR meeting in Paris, the topic of “Innovation Overload” came up in a session on Innovator’s Day; the notion that in certain categories (transcatheter mitral valves and renal denervation, for example), a proliferation of companies threatens to dilute the pool of patients for clinical trials, complicate the issue of physician training, and make fundraising challenging. But there is a positive side, since such activity brings validation and attention to new spaces.
A couple of months ago, my colleague Stephen Levin wrote a Perspective about a concept called “Innovation Overload.” ( See “Innovation Overload in Transcatheter Mitral Valves,” The MedTech Strategist, November 16, 2016.)
